​

Sarepta Therapeutics (SRPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SRPT Stock Forecast

Sarepta Therapeutics (SRPT) stock forecast, based on 55 Wall Street analysts, predicts a 12-month average price target of $24.78, with a high of $35.00 and a low of $14.00. This represents a 58.04% increase from the last price of $15.68.

- $40 $80 $120 $160 $200 High: $35 Avg: $24.78 Low: $14 Last Closed Price: $15.68

SRPT Stock Rating

Sarepta Therapeutics stock's rating consensus is Buy, based on 55 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 31 Buy (56.36%), 18 Hold (32.73%), 6 Sell (10.91%), and 0 Strong Sell (0.00%).

Buy
Total 55 0 6 18 31 Strong Sell Sell Hold Buy Strong Buy

SRPT Price Target Upside V Benchmarks

TypeNameUpside
StockSarepta Therapeutics58.04%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2318
Avg Price Target$23.50$22.00$22.28
Last Closing Price$15.68$15.68$15.68
Upside/Downside49.87%40.31%42.09%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26-6133224
Jun, 26-6133224
May, 26-8123225
Apr, 26-7133225
Mar, 26-7133225
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 09, 2026Piper Sandler$20.00$20.21-1.04%27.55%
Jul 08, 2026Wolfe Research$27.00$20.2133.60%72.19%
May 15, 2026Evercore ISI$19.00$18.204.40%21.17%
Mar 26, 2026Deutsche Bank$14.00$21.68-35.42%-10.71%
Mar 26, 2026Wedbush$35.00$21.6861.44%123.21%
Mar 12, 2026Uy EarMizuho Securities$31.00$17.0481.92%97.70%
Mar 03, 2026Ilya ZubkovLoop Capital Markets$25.00$15.8757.53%59.44%
Mar 03, 2026Andrew TsaiJefferies$30.00$15.9887.73%91.33%
Jan 27, 2026Robert W. Baird$22.00$22.80-3.51%40.31%
Dec 09, 2025Wedbush$32.00$21.8646.39%104.08%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 21, 2026CitigroupSellSellhold
Jul 08, 2026Wolfe ResearchPeer PerformOutperformupgrade
Jul 01, 2026H.C. WainwrightSellSellhold
Apr 16, 2026H.C. WainwrightSellSellhold
Mar 26, 2026Deutsche BankSellSellhold
Mar 26, 2026WedbushOutperformOutperformhold
Mar 26, 2026CitigroupSellSellhold
Mar 03, 2026JefferiesBuyBuyhold
Jan 14, 2026H.C. WainwrightSellSellhold
Dec 09, 2025WedbushBuyOutperforminitialise

Financial Forecast

EPS Forecast

$-10 $-3 $4 $11 $18 $25 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.15$-8.03$-5.80$2.47$-7.13---
Avg Forecast$-5.11$-8.06$-6.57$2.41$11.64$15.52$14.87$15.91
High Forecast$-4.77$-6.17$-6.18$2.94$16.50$21.20$18.54$17.88
Low Forecast$-5.66$-8.95$-7.57$1.72$3.67$10.82$10.96$12.75
Surprise %0.78%-0.37%-11.72%2.49%-161.25%---

Revenue Forecast

$500M $1B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$701.89M$933.01M$1.24B$1.90B$2.20B---
Avg Forecast$695.42M$924.70M$1.23B$1.83B$3.12B$3.94B$4.20B$4.43B
High Forecast$752.63M$1.00B$1.24B$1.86B$3.42B$3.95B$4.22B$4.85B
Low Forecast$659.73M$758.15M$1.21B$1.77B$2.39B$3.93B$4.19B$3.75B
Surprise %0.93%0.90%0.86%4.10%-29.55%---

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-418.78M$-703.49M$-535.98M$235.24M$-713.41M---
Avg Forecast$-435.96M$-421.18M$-535.98M$215.18M$1.10B$1.54B$1.66B$1.47B
High Forecast$-348.77M$-336.95M$-428.78M$271.43M$1.52B$1.96B$1.71B$1.65B
Low Forecast$-523.15M$-505.42M$-643.17M$158.93M$338.71M$999.68M$1.01B$1.18B
Surprise %-3.94%67.03%-9.32%-164.92%---

SRPT Forecast FAQ

Is Sarepta Therapeutics stock a buy?

Sarepta Therapeutics stock has a consensus rating of Buy, based on 55 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 31 Buy, 18 Hold, 6 Sell, and 0 Strong Sell, reflecting a consensus that Sarepta Therapeutics is a favorable investment for most analysts.

What is Sarepta Therapeutics's price target?

Sarepta Therapeutics's price target, set by 55 Wall Street analysts, averages $24.78 over the next 12 months. The price target range spans from $14 at the low end to $35 at the high end, suggesting a potential 58.04% change from the previous closing price of $15.68.

How does Sarepta Therapeutics stock forecast compare to its benchmarks?

Sarepta Therapeutics's stock forecast shows a 58.04% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sarepta Therapeutics over the past three months?

  • July 2026: 0% Strong Buy, 25.00% Buy, 54.17% Hold, 12.50% Sell, 8.33% Strong Sell.
  • June 2026: 0% Strong Buy, 25.00% Buy, 54.17% Hold, 12.50% Sell, 8.33% Strong Sell.
  • May 2026: 0% Strong Buy, 32.00% Buy, 48.00% Hold, 12.00% Sell, 8.00% Strong Sell.

What is Sarepta Therapeutics’s EPS forecast?

Sarepta Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $15.52, marking a -317.67% decrease from the reported $-7.13 in 2025. Estimates for the following years are $14.87 in 2027, and $15.91 in 2028.

What is Sarepta Therapeutics’s revenue forecast?

Sarepta Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $3.94B, reflecting a 79.24% increase from the reported $2.2B in 2025. The forecast for 2027 is $4.2B, and $4.43B for 2028.

What is Sarepta Therapeutics’s net income forecast?

Sarepta Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $1.54B, representing a -316.33% decrease from the reported $-713M in 2025. Projections indicate $1.66B in 2027, and $1.47B in 2028.